Red Queen Bio has successfully raised a $15 million seed round, spearheaded by OpenAI, to pioneer advancements in AI-driven biosecurity. The company emerged from HelixNano and attracted key investors, including Cerberus Ventures, Fifty Years, and Halcyon Futures. The mission of Red Queen Bio is to enhance biological defenses as artificial intelligence technologies evolve. The founders outlined an innovative strategy focused on mapping AI-enabled biothreats and pre-developing medical countermeasures through cutting-edge models, lab automation, and reinforcement learning techniques. Co-founder Hannu Rajaniemi highlighted the announcement of the funding round in a post linking to the company’s website. Notably, OpenAI’s Startup Fund has a history of investing in biosecurity, previously supporting Valthos, a significant player in biosecurity software. This funding marks a crucial step in the intersection of AI and public health, positioning Red Queen Bio at the forefront of biosecurity innovation.
Source link
